EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

BMC Cancer

Table 2 Correlation of EVI1 expression with therapy response and clinical outcomes in the entire cohort

Endpoint	Category	Odds ratio/ Hazard ratio (95% CI)	p-value*
pCR (ypT0 ypN0)	EVI1 continuous	1.16 (0.82–1.65)	0.404
DFS	EVI1 continuous	0.89 (0.70–1.12)	0.305
OS	EVI1 continuous	0.81 (0.61–1.07)	0.129
pCR (ypT0 ypN0)	EVI1 high vs low	1.25 (0.89–1.74)	0.197
DFS	EVI1 high vs low	0.91 (0.71–1.17)	0.460
OS	EVI1 high vs low	0.85 (0.62–1.15)	0.293

Note, for regression analyses EVI1 continuous expression was transformed at units log10 increase
CI Confidence interval, pCR Pathological complete response, DFS Disease-free survival OS overall survival
^* for EVI1 as continuous variable p-values according to regression logistic (pCR) and Cox (DFS and OS) analyses, for EVI1 as dichotomized variable p-values according to regression logistic (pCR) analysis and log-rank test (DFS and OS)

ISSN: 1471-2407